What is a stock summary page? Click here for an overview.
Business Description
Co-Diagnostics Inc
NAICS : 325413
SIC : 5047
ISIN : US1897631057
Share Class Description:
CODX: Registered ShsDescription
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.9 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.53 | |||||
| Beneish M-Score | -3.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -55.7 | |||||
| 3-Year Book Growth Rate | 5.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.63 | |||||
| 9-Day RSI | 37.39 | |||||
| 14-Day RSI | 35.87 | |||||
| 3-1 Month Momentum % | -31.57 | |||||
| 6-1 Month Momentum % | -55.64 | |||||
| 12-1 Month Momentum % | -53.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.92 | |||||
| Quick Ratio | 6.7 | |||||
| Cash Ratio | 6.5 | |||||
| Days Inventory | 205.8 | |||||
| Days Sales Outstanding | 23.38 | |||||
| Days Payable | 176.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.1 | |||||
| Shareholder Yield % | -4.76 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.76 | |||||
| Operating Margin % | -562.89 | |||||
| Net Margin % | -580.96 | |||||
| FCF Margin % | -377.75 | |||||
| ROE % | -51.6 | |||||
| ROA % | -46.52 | |||||
| ROIC % | -122.25 | |||||
| 3-Year ROIIC % | -537.53 | |||||
| ROC (Joel Greenblatt) % | -644.73 | |||||
| ROCE % | -48.01 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.75 | |||||
| PB Ratio | 0.21 | |||||
| Price-to-Tangible-Book | 0.35 | |||||
| EV-to-EBIT | 0.51 | |||||
| EV-to-EBITDA | 0.53 | |||||
| EV-to-Revenue | -2.89 | |||||
| EV-to-Forward-Revenue | 0.31 | |||||
| EV-to-FCF | 0.76 | |||||
| Price-to-GF-Value | 0.67 | |||||
| Price-to-Projected-FCF | 0.16 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.46 | |||||
| Earnings Yield (Greenblatt) % | 196.08 | |||||
| FCF Yield % | -201.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CODX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Co-Diagnostics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.106 | ||
| EPS (TTM) ($) | -1.38 | ||
| Beta | 1.42 | ||
| 3-Year Sharpe Ratio | -0.86 | ||
| 3-Year Sortino Ratio | -1 | ||
| Volatility % | 55.67 | ||
| 14-Day RSI | 35.87 | ||
| 14-Day ATR ($) | 0.063482 | ||
| 20-Day SMA ($) | 0.48981 | ||
| 12-1 Month Momentum % | -53.45 | ||
| 52-Week Range ($) | 0.4 - 2.2299 | ||
| Shares Outstanding (Mil) | 31.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Co-Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Co-Diagnostics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Co-Diagnostics Inc Frequently Asked Questions
What is Co-Diagnostics Inc(CODX)'s stock price today?
The current price of CODX is $0.42. The 52 week high of CODX is $2.23 and 52 week low is $0.40.
When is next earnings date of Co-Diagnostics Inc(CODX)?
The next earnings date of Co-Diagnostics Inc(CODX) is 2025-03-27.
Does Co-Diagnostics Inc(CODX) pay dividends? If so, how much?
Co-Diagnostics Inc(CODX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers